Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Short Interest Down 26.5% in December

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 29,780 shares, a decrease of 26.5% from the December 15th total of 40,499 shares. Based on an average daily trading volume, of 45,777 shares, the short-interest ratio is presently 0.7 days. Approximately 4.1% of the company’s stock are short sold. Approximately 4.1% of the company’s stock are short sold. Based on an average daily trading volume, of 45,777 shares, the short-interest ratio is presently 0.7 days.

Quoin Pharmaceuticals Stock Down 3.7%

Shares of Quoin Pharmaceuticals stock opened at $10.27 on Friday. Quoin Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $41.80. The firm’s 50 day moving average is $14.59 and its two-hundred day moving average is $10.91. The firm has a market capitalization of $8.63 million, a P/E ratio of -0.32 and a beta of 1.59.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($6.71) EPS for the quarter, missing the consensus estimate of ($6.36) by ($0.35). As a group, research analysts expect that Quoin Pharmaceuticals will post -2.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QNRX has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Monday, December 22nd. Wall Street Zen upgraded shares of Quoin Pharmaceuticals to a “sell” rating in a research note on Saturday, November 15th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Aberdeen Group plc acquired a new stake in Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 75,000 shares of the company’s stock, valued at approximately $1,082,000. Aberdeen Group plc owned about 8.93% of Quoin Pharmaceuticals at the end of the most recent quarter. 8.63% of the stock is owned by institutional investors.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.